» Articles » PMID: 32077338

Contralateral Prophylactic Mastectomy in Breast Cancer: What to Discuss with Patients

Overview
Specialties Oncology
Pharmacology
Date 2020 Feb 21
PMID 32077338
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

: The contralateral prophylactic mastectomy (CPM) rate in the U.S. has been steadily increasing. This is of particular concern because many women who undergo this procedure are candidates for breast-conserving surgery.: CPM's medical benefit is related to the risk of contralateral cancer development and whether CPM provides a survival benefit. Contralateral cancer rates have decreased, and CPM does not provide a survival benefit. Other potential benefits of the procedure may be improved quality of life; these data are reviewed. Research efforts have been undertaken to better understand the decision-making process of patients who consider, and ultimately undergo, this procedure.: Decisional traits, personal values, the desire for peace of mind, and the desire to obtain breast symmetry are important factors that drive a woman's decision to undergo CPM. Additionally, many patients lack the knowledge on how different types of breast surgery impact outcomes. To improve the shared decision-making process, a stepwise approach to address possible misconceptions, and clarify the real risks/benefits of this procedure should be utilized. A clear recommendation (for/against) should be made for every patient with newly diagnosed breast cancer who considers CPM. Communication tools to assist patients and surgeons in this process are sorely needed.

Citing Articles

Reducing Disparities: Regional Anesthesia Blocks for Mastectomy with Reconstruction Within Standardized Regional Anesthesia Pathways.

Vingan P, Serafin J, Boe L, Zhang K, Kim M, Sarraf L Ann Surg Oncol. 2024; 31(6):3684-3693.

PMID: 38388930 PMC: 11267583. DOI: 10.1245/s10434-024-15094-2.


Society of Surgical Oncology Breast Disease Site Working Group Statement on Contralateral Mastectomy: Indications, Outcomes, and Risks.

Singh P, Agnese D, Amin M, Barrio A, van den Bruele A, Burke E Ann Surg Oncol. 2024; 31(4):2212-2223.

PMID: 38261126 DOI: 10.1245/s10434-024-14893-x.


Satisfaction and Well-Being After Contralateral Prophylactic Mastectomy Among BRCA Mutation Carriers and Noncarriers: A Longitudinal Analysis of BREAST-Q Domains.

Myers S, Tadros A, Sevilimedu V, Nelson J, Le T, Garcia P Ann Surg Oncol. 2023; 30(12):7116-7123.

PMID: 37581851 PMC: 10996069. DOI: 10.1245/s10434-023-14086-y.


Contralateral Prophylactic Mastectomy Decision-Making: The Partners' Perspective.

Nash A, Bloom D, Chapman B, Wheeler S, McGuire K, Lee C Ann Surg Oncol. 2023; 30(10):6268-6274.

PMID: 37573282 DOI: 10.1245/s10434-023-14022-0.


Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies.

Bharmjeet , Das A Cancer Rep (Hoboken). 2023; 6 Suppl 1:e1807.

PMID: 36971312 PMC: 10440846. DOI: 10.1002/cnr2.1807.


References
1.
Yao K, Belkora J, Sisco M, Rosenberg S, Bedrosian I, Liederbach E . Survey of the Deficits in Surgeons' Knowledge of Contralateral Prophylactic Mastectomy. JAMA Surg. 2015; 151(4):391-3. PMC: 6066280. DOI: 10.1001/jamasurg.2015.3601. View

2.
. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001):1341-1352. DOI: 10.1016/S0140-6736(15)61074-1. View

3.
Zhang B, Coopey S, Gadd M, Hughes K, Chang D, Oseni T . Trends in Unilateral and Contralateral Prophylactic Mastectomy Use in Ductal Carcinoma In Situ of the Breast: Patterns and Predictors. Ann Surg Oncol. 2019; 26(12):3863-3873. DOI: 10.1245/s10434-019-07628-w. View

4.
Grimmer L, Liederbach E, Velasco J, Pesce C, Wang C, Yao K . Variation in Contralateral Prophylactic Mastectomy Rates According to Racial Groups in Young Women with Breast Cancer, 1998 to 2011: A Report from the National Cancer Data Base. J Am Coll Surg. 2015; 221(1):187-96. DOI: 10.1016/j.jamcollsurg.2015.03.033. View

5.
Pesce C, Liederbach E, Wang C, Lapin B, Winchester D, Yao K . Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014; 21(10):3231-9. DOI: 10.1245/s10434-014-3956-3. View